… Ultimately, we believe that testing for these biomarkers will greatly enhance drug therapy,
making drug products safer to use, while at the same time making efficacious outcomes more …

… therapy or may lead to complications among patients whose treatment is already underway.
We therefore review the clinical … (BUP) and antiretroviral therapies and provide an approach …

… In the following, we highlight selected pharmacogenomic examples that impact clinical
practice and refer to the primary references provided in Tables 2 and 3 as well as to …

… a versatile, emerging clinical technology promising to … the drug-eluting stent have heralded
the entrance, and significantly, routes to FDA approval, for these devices into clinical practice. …

… This variability helps to explain unpredictable responses to existing drug therapies that have
been observed so far. Largescale expression monitoring on microarrays has provided the …

… Accumulating evidence suggests, however, that these agents are underutilized in clinical
practice due to low rates of prescribing among persons at high risk of fracture, and also poor …

… In addition, these guidelines describe administration of therapies in clinical practice; … of
clinical trials, given that such clinical studies are designed to test innovative and novel therapies …

… therapy, including the optimal dose of aspirin, the variable balance of benefits and hazards in
… clinical settings, and the issue of interindividual variability in response to antiplatelet drugs. …

… There is no doubt that drug-resistance assays have achieved sufficient technological maturity
to be introduced into clinical practice. However, the information they provide seems to be …

… In line with clinical practice, evidence from clinical trials indicate that most hypertensive
patients need two or more drugs for adequate BP control. On the other hand, complex medication …